Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HT-4253
- Development stage
- Phase 2
- Lead developer
- Halia Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HT-4253 is an orally administered small molecule drug developed by Halia Therapeutics. It acts as a potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2), a key mediator of neuroinflammation implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. By inhibiting LRRK2, HT-4253 aims to reduce chronic brain inflammation, potentially altering the progression of these diseases. The drug demonstrates excellent brain penetration and is currently being evaluated in Phase 1 clinical trials for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
02
Targets
LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2)
Beyond the preview
Go deeper on HT-4253.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HT-4253.